Genetic predictors of response to antidepressants in the GENDEP project
Open Access
- 14 April 2009
- journal article
- research article
- Published by Springer Science and Business Media LLC in The Pharmacogenomics Journal
- Vol. 9 (4), 225-233
- https://doi.org/10.1038/tpj.2009.12
Abstract
The objective of the Genome-based Therapeutic Drugs for Depression study is to investigate the function of variations in genes encoding key proteins in serotonin, norepinephrine, neurotrophic and glucocorticoid signaling in determining the response to serotonin-reuptake-inhibiting and norepinephrine-reuptake-inhibiting antidepressants. A total of 116 single nucleotide polymorphisms in 10 candidate genes were genotyped in 760 adult patients with moderate-to-severe depression, treated with escitalopram (a serotonin reuptake inhibitor) or nortriptyline (a norepinephrine reuptake inhibitor) for 12 weeks in an open-label part-randomized multicenter study. The effect of genetic variants on change in depressive symptoms was evaluated using mixed linear models. Several variants in a serotonin receptor gene (HTR2A) predicted response to escitalopram with one marker (rs9316233) explaining 1.1% of variance (P=0.0016). Variants in the norepinephrine transporter gene (SLC6A2) predicted response to nortriptyline, and variants in the glucocorticoid receptor gene (NR3C1) predicted response to both antidepressants. Two HTR2A markers remained significant after hypothesis-wide correction for multiple testing. A false discovery rate of 0.106 for the three strongest associations indicated that the multiple findings are unlikely to be false positives. The pattern of associations indicated a degree of specificity with variants in genes encoding proteins in serotonin signaling influencing response to the serotonin-reuptake-inhibiting escitalopram, genes encoding proteins in norepinephrine signaling influencing response to the norepinephrine-reuptake-inhibiting nortriptyline and a common pathway gene influencing response to both antidepressants. The single marker associations explained only a small proportion of variance in response to antidepressants, indicating a need for a multivariate approach to prediction.Keywords
This publication has 37 references indexed in Scilit:
- Measuring depression: comparison and integration of three scales in the GENDEP studyPsychological Medicine, 2007
- Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controlsNature, 2007
- Handling drop‐out in longitudinal clinical trials: a comparison of the LOCF and MMRM approachesPharmaceutical Statistics, 2007
- Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment responseProceedings of the National Academy of Sciences of the United States of America, 2006
- European Population Substructure: Clustering of Northern and Southern PopulationsPLoS Genetics, 2006
- Variation in the Gene Encoding the Serotonin 2A Receptor Is Associated with Outcome of Antidepressant TreatmentAmerican Journal of Human Genetics, 2006
- Efficiency and power in genetic association studiesNature Genetics, 2005
- Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatmentNature Genetics, 2004
- Statistical significance for genomewide studiesProceedings of the National Academy of Sciences of the United States of America, 2003
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979